Tvardi Therapeutics reports third quarter 2025 results and updates on clinical programs

Reuters

2025/11/14

Tvardi <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter 2025 results and updates on clinical programs

Tvardi Therapeutics Inc. reported cash, cash equivalents and short-term investments of $36.5 million as of September 30, 2025, up from $31.6 million at December 31, 2024. Research and development expenses for the third quarter of 2025 were $3.6 million, a decrease from $4.8 million in the same period of 2024, primarily due to lower costs related to TTI-101 trials and the completion of the IPF trial in the second quarter of 2025. These decreases were partially offset by a $2.0 million increase in expenses associated with the healthy volunteer study of TTI-109. Tvardi stated that its current cash runway is expected to fund operations into the fourth quarter of 2026. The company continues to advance its Phase 2 study of TTI-101 in hepatocellular carcinoma, with topline data expected in the first half of 2026, and has initiated a healthy volunteer study for TTI-109, with results also anticipated in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113079476) on November 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583178511"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583178511\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583178511?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583178511","market":"nz","top_or_hot":-1,"title":"Tvardi Therapeutics reports third quarter 2025 results and updates on clinical programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports third quarter 2025 results and updates on clinical programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TVRD\">Tvardi Therapeutics Inc</a>. reported cash, cash equivalents and short-term investments of $36.5 million as of September 30, 2025, up from $31.6 million at December 31, 2024. Research and development expenses for the third quarter of 2025 were $3.6 million, a decrease from $4.8 million in the same period of 2024, primarily due to lower costs related to TTI-101 trials and the completion of the IPF trial in the second quarter of 2025. These decreases were partially offset by a $2.0 million increase in expenses associated with the healthy volunteer study of TTI-109. Tvardi stated that its current cash runway is expected to fund operations into the fourth quarter of 2026. The company continues to advance its Phase 2 study of TTI-101 in hepatocellular carcinoma, with topline data expected in the first half of 2026, and has initiated a healthy volunteer study for TTI-109, with results also anticipated in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113079476) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tvardi Therapeutics reports third quarter 2025 results and updates on clinical programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTvardi Therapeutics reports third quarter 2025 results and updates on clinical programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports third quarter 2025 results and updates on clinical programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TVRD\">Tvardi Therapeutics Inc</a>. reported cash, cash equivalents and short-term investments of $36.5 million as of September 30, 2025, up from $31.6 million at December 31, 2024. Research and development expenses for the third quarter of 2025 were $3.6 million, a decrease from $4.8 million in the same period of 2024, primarily due to lower costs related to TTI-101 trials and the completion of the IPF trial in the second quarter of 2025. These decreases were partially offset by a $2.0 million increase in expenses associated with the healthy volunteer study of TTI-109. Tvardi stated that its current cash runway is expected to fund operations into the fourth quarter of 2026. The company continues to advance its Phase 2 study of TTI-101 in hepatocellular carcinoma, with topline data expected in the first half of 2026, and has initiated a healthy volunteer study for TTI-109, with results also anticipated in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113079476) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVRD","symbol_name":"Tvardi Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL5l44wY:1","article_id":"2583178511","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583178511","pubTimestamp":1763067728,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tvardi Therapeutics Inc. reported cash, cash equivalents and short-term investments of $36.5 million as of September 30, 2025, up from $31.6 million at December 31, 2024. Research and development expenses for the third quarter of 2025 were $3.6 million, a decrease from $4.8 million in the same period of 2024, primarily due to lower costs related to TTI-101 trials and the completion of the IPF trial in the second quarter of 2025. These decreases were partially offset by a $2.0 million increase in expenses associated with the healthy volunteer study of TTI-109. Tvardi stated that its current cash runway is expected to fund operations into the fourth quarter of 2026. The company continues to advance its Phase 2 study of TTI-101 in hepatocellular carcinoma, with topline data expected in the first half of 2026, and has initiated a healthy volunteer study for TTI-109, with results also anticipated in the first half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVRD":"Tvardi Therapeutics Inc","BK4007":"制药"},"translate_title":"Tvardi Therapeutics报告2025年第三季度结果和临床项目更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVRD":0.9},"content_text":"Tvardi Therapeutics reports third quarter 2025 results and updates on clinical programs\n    \n\nTvardi Therapeutics Inc. reported cash, cash equivalents and short-term investments of $36.5 million as of September 30, 2025, up from $31.6 million at December 31, 2024. Research and development expenses for the third quarter of 2025 were $3.6 million, a decrease from $4.8 million in the same period of 2024, primarily due to lower costs related to TTI-101 trials and the completion of the IPF trial in the second quarter of 2025. These decreases were partially offset by a $2.0 million increase in expenses associated with the healthy volunteer study of TTI-109. Tvardi stated that its current cash runway is expected to fund operations into the fourth quarter of 2026. The company continues to advance its Phase 2 study of TTI-101 in hepatocellular carcinoma, with topline data expected in the first half of 2026, and has initiated a healthy volunteer study for TTI-109, with results also anticipated in the first half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113079476) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}